Reserpine, an alkaloid derived from the Asian plant Rauwolfia serpentina, has been used as a prescription medication for many years. It was'first recommended as a tranquilizer in various anxiety states but now is used primarily as an efficaceous antihypertensive agent for mild forms of hypertension. Reserpine's antihypertensive action is attributed to its norepinephrine-blocking capacity at receptors on post-ganglionic nerve endings of the sympathetic nervous system. As a result, norepinephrine levels are depleted in the brain, heart, adrenal medulla, and adrenergic nerve endings.
In 1974, an analysis made by the Boston Collaborative Drug Surveillance Group of several epidemiological studies appeared to indicate that women receiving long-term therapy with reserpine had an increased incidence of breast cancer. Later studies did not corroborate these findings but the controversy triggered the initiation of a bioassay in rats and mice by NCI. The 2-year carcinogenicity studies were conducted by the Southern Research Institute, Birmingham, Alabama and results ' The contents of this communication are based upon presentations made by Dr. Robert M. Dicner and/or Dr. Samuel W. Thompson A draft report, which first became available in mid February of 1979, revealed that groups of 50 male and 50 female F344 rats and B6C3F1 mice had been treated with 0, 5, and 10 ppm reserpine in the diet for 103 weeks. The dosed male rats had an increased incidence of adrenal medullary pheochromocytomas while male mice developed undifferentiated carcinomas of the seminal vesicles and female mice had a n increased incidence of mammary cancer. It was concluded that "reserpine was carcinogenic in male rats and in mice of both sexes producing three different kinds of cancers."
These findings were startling in light of two long term studies which had previously been conducted in rats (5, 26) and which indicated no tumor increase in any of the treated groups of animals.
The results, conclusions and interpretations emanating from the NCI report were contested before the Data Evaluation/Risk Assessment Subgroup of the Clearinghouse on Environmental Carcinogens on May 1, 1979, and .February 15, 1980, and the Cardio-Renal Advisory Committee of the Food and Drug Administration on June 22 and November 19, 1979 . In addition, during the summer and fall of 1979 two teams of independent pathology consultants reviewed the histopathology slides of the controversial tumors from the rat adrenal glands and mouse mammary glands and seminal vesicles. No unanimity of opinion was achieved between the various groups. However, serious deficiencies in the preparation and interpretation of the pathology material were confirmed and necessitated some revision of the original report, although adequate and appropriate corrections were never made to reflect the views of the consultants.
The purpose of this communication is to present the reader with a pictorial overview of the key findings and arguments supporting the contention that reserpine should not be classified as a carcinogen. Each of the three controversial tumor sites will be discussed under its own heading.
RAT ADRENAL MEDULLA
The data describing an increased incidence . of so-called pheochromocytomas in male rats in the reserpine bioassay was especially perplexing in view of the known effects of reserpine on the adrenal medulla of rodents as well as man (9, 13, 18, 25) . Reserpine blocks catecholamine synthesis in the adrenal medulla of the rat. This 'occurs when dopamine uptake into the chromaffin granules is blocked by reserpine, resulting in an inhibition of dopamine conversion into norepinephrine, a reaction which takes place within the granule matrix. Blocking of dopamine uptake follows the irreversible binding of reserpine to the external surface of the chromaffin granule membrane (25). Studies have shown that one molecule of reserpine can prevent the synthesis of several thousand molecules of norepinephrine (13). These facts suggest the biological improbability of producing, in reserpine medicated rats, adrenal medullary tumors which would synthesize, store, and possibly secrete increased quantities of norepinbphrine/epinephrine as occurs in pheochromocytomas found in man.
Ideally, in order to assess the incidence of any type of histological deviation from normal adrenal medulla in the rat, it would be necessary to employ serial section techniques and sequentially examine all sections microscopically. Such procedures in drug safety evaluation are not feasible. However, in the absence of serial sections, it is essential that a representative section of the adrenal medulla be examined, preferably a transverse or longitudinal section taken at its greatest diameter ( Figure 1 ). The importance of such a representative tissue section becomes of paramount importance when one considers the heterogeneous cell populations present within the rat adrenal medulla. The medulla of the rat, unlike man, is populated by three types of medullary secretory cells, two of which are chromaffin positive ( Figure 1 ). Both of the latter cell types are either epinephrine or norepinephrine storing cells. The norepinephrine storing cells do not contain acid phosphatase I k . *
FIG. I-Adrenal gland from a normal Sprague-Dawley rat. This tissue section has been exposed to K2Cr207/K2Cr04-Chromaffin Reaction-for the demonstration of epinephrine/norepinephrine-containing medullary secretory cells which comprise most of the cell population in the medulla. At a higher magnification islets of non-chromaffin medullary secretory cells can be discerned, however. This specimen contains a good representative cross-section of medullary tissue: 45X.
while the epinephrine storing cells yield an intensive positive reaction ( Figure 2 ). Thus, within the rat adrenal medulla a heterogeneity of cell types are organized into randomly scattered islets distributed throughout the medulla. An adequate exposure of medullary surface area should include a sufficient number of cells to insure a proper representative of all three cell types in the absence of histochemical verification. If the section which first appears is not representative, an additional section which is representative should be prepared and examined. If artifacts which can obscure diagnosis or render a section uninterpretable are present in the initial preparation, an effort should be made to obtain a representative section without artifacts. If an adequately sampled tissue specimen or suitable section free of artifact cannot be obtained, the medulla in question should be deleted from the denominators for adrenal medullas when lesion incidence ratios are prepared.
In the authors' counting system, the following logic is used to derive the denominators for paired adrenal medullas within a study: Each Pair of Adrenal Glands-1) If gland is bilaterally missing-reduce denominator by one (1) . 2) If gland is unilaterally missing, no lesion present in the opposite gland-reduce denominator by one (1) . If a deviation is present in the medulla of the opposite gland-include in the denominator for paired glands. 3) If medulla is missing within the tissue section of one gland while no deviation is present in the medulla of the opposite gland-reduce the denominator b y one ( 1 ) . If a lesion is present in the medulla of the opposite gland-include in the denominator for paired glands. 4) If: a) the medulla is missing within both tissue sections or b) too few medullary secretory cells are included within the tissue sections or c) medullas are present but not readable due to artifacts-reduce the denominator by one (1) . 5) If: a) the medulla is missing in the tissue section of one gland or b) too few medullary secretory cells are included within the tissue section of one gland or c) the medulla of one gland is not readable due to artifacts and no lesion is present in the medulla of the opposite gland-reduce the denominator by one (1) . If a deviation is present in the medulla of the opposite gland-include in the denominator for paired glands. "The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which stances, the denominators included only those animals for which that site was examined histologically." This statement did not apply for changes in the adrenal medulla of any rat. In fact, if one &re to use strict, scientifically correct criteria (as previously described) to assess the histologic morpho~ogy of the adrenal medulla in the male animals, only 65% of the male animals were examined. Instead, the NCI report glands as the denominators for male rat adrenal medullas which yielded the following misleading results: 48/49 control, 49/50 low that site is examined (denominator). In most in-utilized denominators of paired adrenal voi. 8, NO. 2, 1980 BIOASSAY OF RESERPINE dose, and 48/50 high dose animals examined. Actually, representative tissue sections of medullas were present in only 29/48 control, 36/ 49 low dose, and 28/47 high dose animals ( Table I) . Table I also depicts the number of adrenal glands observed within the specimen file of the Reserpine Bioassay versus the number cited in the report. As noted, numerators for the analysis of the data appear considerably diminished following a scientifically rigorous examination. Such a situation constitutes sub-sampling and it has been well documented that sub-sampling precludes an accurate assessment of lesion incidence (27) . Therefore, it appears that analyses of the incidence of adrenal proliferative lesions in question are scientifically invalid as presented in the NCI report. Table I1 depicts the primary and secondary proliferative lesions in the tissue specimens of adrenal medullas from male rats which were observed by the authors, as well as those noted in the NCI report. The NCI report inpicates that 1/48 control, 4/49 low dose, and '9/ 48 high dose male rats had malignant pheochromocytomas while 1/48 control, 16/49 low dose, and 13/48 high dose male rats had benign pheochromocytomas. None of these deviations were characterized by a diagnostic positive chromaffin reaction. In man, the histologic diagnosis of pheochromocytoma is never complete, or even established, unless the presence of catecholamines is confirmed via biochemical or histochemical means. No histochemical, biochemical, clinical or morphologic evidence was presented in the NCI report, or established during the authors' review of the tissue sections, to prove that the entities designated as pheochromocytomas were able to synthesize, store and/or secrete increased quantities of epinephrine or norepinephrine and were therefore comparable to the pheochromocytomas of man. The criteria stated in the NCI report for the diagnosis of malignant pheochromocytoma is not acceptable in human or veterinary pathology in that no evidence was presented to indicate that these proliferative entities had penetrated the adrenal connective tissue capsule or that metastasis to extra adrenal sites had occurred. The latter two criteria are essential for a valid diagnosis of malignant pheochromocytoma, in addition to the establishment of the presence of catecholamines (1, 2, 4, 10, 12, 14, 15, 19, 22, 24) . Thus the diagnoses of pheochromocytoma were based on convenience rather than scientific fact. Furthermore, the patterns of growth for these proliferative lesions in most instances are compatible with a metastatic neoplasm within the adrenal medulla, although in one low dose animal a neuroblastoma was observed (Figure 6 
.)
Thirteen proliferative lesions in the adrenal medullas of control male animals which were histologically similar to those classified as benign pheochromocytomas in the treated animals were either unrecorded or missed in the original report (representative example depicted in Figure 7 ). In fact, the classification of medullary hyperplasia was omitted in the original report, although the incidence for this particular deviation within the National Bioassay Program itself is reported to be a minimum of 2.7%.
The criteria for adrenal medullary hypferplasia are well documented in the literature and are easily recognized. The lesion consists of focal aggregates of hypercellular islets of medullary secretory cells which evidence increased basophilia and are surrounded by re-NCI C'ba-Ceigy Using Unsubstan. Denom.
Using True Denom. ticular connective tissue ( Figure 8 ). The focus has irregular boundaries which gradually blend into the adjacent medullary parenchyma. The chromaffin reaction is usually less intense within foci of medullary hyperplasia when compared to normal medullary secretory cells.
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Via split image comparison microscopy, f e w differences were observed between the histopathologic deviation classified as adrenal medullary hyperplasia within control males versus those entities categorized as pheochromocytoma in the treated groups by NCI (Figure 9 ). Tintorial qualities, as they relate to variances in stain composition and staining procedures, were the only detectable differ- ences. Such "c,ontrol versus treated" comparisons were made with so-called benign or malignant pheochromocytomas in 12/36 low dose and 13/28 high dose animals. In addition, foci of adrenal medullary hyperplasia were discovered in 3/36 low dose and 1/28 high dose animals which were not even described in the original NCI report.
There were also instances where benign adrenal medullary neoplasia was observed by the authors. The criteria for benign adrenal medullary secretory cell neoplasia (adenomas) are cited in the literature and the features associated with this entity are easily recognized. The lesion consists of focal aggregates of hypercellular islets composed of medullary secretory cells which evidence increased basophilia (Figure 10) . The tumors have irregular boundaries which do not blend into the surrounding parenchyma as does medullary secretory cell hyperplasia. Benign medullary tumors expand to noticeably compress adjacent parenchyma and are separated from the lattFr by bands of reticular fibers. Chromaffin reactions which yield a less intense or equal response are observed in these tumors when compared to tissue specimens of normal medullary secretory cells following the same histochemical procedure.
In the normal rat adrenal medulla, both epinephrine and norepinephrine storing/secretory cells are innervated by preganglionic nerve fibers of the splanchnic/sympathetic nervous system. Foci of hyperplastic medullary secretory cells, as well as adrenal medullary adenomas, maintain an intimate relationship with these arborizing nerve branches as noted in Figure 11 . Bodian's Protargal technique and McManus' Chloral Hydrate silver procedure may both be applied for the identification of neurofibrils as well as reticular connective tissue thereby providing an effective approach toward distinguishing between hyperplastic foci and adenomas as depicted in Figure 11 and 12 (28) . Such stains were not employed during the conduct of the bioassay to differentiate adrenal medullary hyperplasia versus adrenal medullary adenoma. As cited in Table 11 , benign medullary secretory cell tumors were observed in 1/29 control, 4/36 low dose and 3/28 high dose male rats. A typical example of this type of lesion is depicted in Figure 13 . Similar entities were at times designated as a benign or malignant pheochromocytoma in the NCI report. Without the support of scientifically valid criteria and the necesssary histochemical, biochemical and/or clinical parameters, such diagnoses are without meaning.
Metastatic tumors in the adrenal medulla occur frequently in man. According to Karsner adrenal. When there are several metastases in an adrenal, they may vary considerably in size. Secondary tumors may attain great size, up to about 300 grams, in which instance the masses may be irregular in outline or conform roughly to that of the adrenal. Direct extension beyond the confines of the adrenal may take place. As with metastases in general, the degree of differentiation is usually but not invariably that of the primary tumor."
In the experience of the authors, a meta-static tumor may or may not be composed of cell types which are difficult to distinguish from adrenal medullary secretory cells in routine hematoxylin and eosin stained preparations ( Figure 14 ). Logically, cells comprising a metastatic tumor would not be expected to establish neural connections as would a normal medullary parenchyma or even a primary proliferative lesion.
Several investigators have reported an ap- parent increased incidence of so-called pheochromocytomas in rats which also harbored interstitial cell tumors of the testes (21) . According to Mostofi and Bresler (16), about 10% of Leydig cell tumors observed in rats are malignant with metastasis as the most reliable criterion for malignancy. Leydig cell tumors of the testes in the rat are composed of varying numbers of four basic cell types ( Figure 15 ).
Many of the cells within these tumors appear virtually indistinguishable from adrenal medullary secretory cells in hematoxylin and eosin stained preparations. It is important to
re-emphasize the fact that although some Leydig cell tumors of the rat may be composed of innocuous, benign-appearing cell populations, up to 10% of these neoplasms may metastasize. The male rats used in the bioassay bore a greater than 75% incidence of Leydig cell tumors of the testis, an example of which is presented in Figure 16 . It would not be out of context to expect a certain percentage of these neoplasms to have metastasized to the adrenal medullas of male rats in which so-called pheochromocytomas were diagnosed. Of the male rats which were afflicted with so-called malignant pheochromocytomas, 1/29 control, 2/ 36 low dose and 4/28 high dose animals bore ,leoplasms with circumferential growth patterns typical of a metastatic tumor within the adrenal medulla ( Figure 17 ).
In summary, the statement that an increased incidence of adrenal pheochromocytomas occurred in male F344 rats fed reserpine under the conditions of the bioassay is not supported by fact because of the gross defi- ciencies reflected in the conduct of the histopathology examinations as described above. The absence of representative sections of adrenal medullary tissue in all but 65% of the agnoses on selected controversial histological slides and therefore refrained from making any comments regarding the interpretation of the study results. test animals (denominators) precludes a meaningful evaluation of this organ. This view MOUSE SEMINAL VESICLE was shared also by one groupof consultant expert pathologists who were requested to review the study. The second group of consultants were requested only to give their di-The property of reserpine to suppress gonadotrophic hormone synthesis renders it an unlikely candidate for the stimulation of primary neoplasia within the seminal vesicles and/or prostate gland in any animal species, including man. Table I11 depicts the observations made relative to the nonneoplastic lesions within the seminal vesicles of male mice. In the NCI report, denominators for the seminal vesicles were given as 50 for control, 50 in the low dose group and 49 in the high dose group. In the authors' review of the tissue sections, these secondary sex organs were not present in one control and one low dose animal so that the true denominators were 49 in the control group, 49 in the low dose group and 49 in the high dose group.
Obstruction of the ducts leading from the seminal vesicles results in their distension and may occur either unilaterally or bilaterally. A potential cause of such an obstruction may result as a consequence of hormonally-induced squamous metaplasia. A more frequent cause results from the plugging of the urethra and ducts with inspissated sperm or sperm granulomas. The NCI report made no mention of duct obstruction or of distension of the seminal vesicles in any control or treated mouse. However, during the authors' review of the tissue sections, unilateral/bilateral distension of this organ was observed in 12/49 controls, 13/49 low dose, and 5/49 high dose mice. Also, ducts of the seminal vesicles at the level of the colliculus seminalis were not included within the sections of 36/49 controls. As seminal vesicle ducts at the level of the colliculus seminalis were not present in 4/12 control animals which bore distended glands, it was not possible to determine the cause of the distension in these four animals. The ducts of the seminal vesicles at this level were present in 4/13 low dose and 3/5 high dose mice which bore distended glands. In each instance
TABLE Ill-Non-Neoplastic Lesions of Seminal Vesicles
it was observed that the distension was caused by duct and/or urethral obstruction in the form of sperm granulomas such as the one depicted in Figure 18 . None of the above observations were described in the NCI report.
A statistically significant incidence of chronic vesiculitis, with or without fibrosis, and hypertrophy of the muscularis and/or myoepithelium, was described in the NCI report as occurring in 13/50 low dose (actually 13/49) male mice when compared to control animals. Although the NCI report does not describe any instances of chronic vesiculitis within the control animals, frank, chronic vesiculitis was observed by the authors in 9/49 control animals. Therefore, there is no significant difference in the incidence of vesiculitis in the controls versus either treated group.
Protracted administration of large doses of hormones such as estrogen may cause hyperplasia and metaplasia in rodent secondary sex organs (3). The NCI report cited epithelial hyperplasia within the seminal vesicles in 4/ 50 low dose (actually 4/49), and 4/49 high dose male mice. .The authors observed the same type of epithelial foci in the seminal vesicles of 5/49 control male mice; however, these observations were not cited in the NCI report. Based on a thorough examination of the relevant tissue sections, there was no evidence of epithelial hyperplasia in any of the seminal vesicles throughout the study. The socalled hyperplasias, as described in the NCI report, were sectioning artifacts (29) caused by tangentially cut sections. Such sections give the appearance of an epithelium which is thicker than one cell layer, especially in the villous infoldings and projections of secretory areas which may easily be mistaken for foci NCI Ciba-Ceigy of hyperplasia. In the absence of epithelial hyperplasia in the coagulating gland and/or urethral end of the ducts, caution must be exercised when making a diagnosis of hyperplasia in the seminal vesicles of mice. Tumors of the seminal vesicles of mice are rare (23) . As far as we can determine, only four instances of so-called spontaneous seminal vesicle tumors within mice have been reported in the literature: 1) papillary adenoma (30); 2) "polymorphic sarcoma" (25); 3) "hemorrhagic sarcoma" (11); and 4) papillary adenocarcinoma (20) . From a review of the cited literature it appears that two of these four tumors were metastatic to the seminal vesicles and that only the papillary adenoma and the papillary adenocarcinoma were primary tumors within the seminal vesicles. According to Franks (8), the prostate and seminal vesicles are often infiltrated by tumors arising in or involving the peritoneal cavity. Also, tumor metastases are often found in the periprostatic tissues in animals with neoplasmsjof the reticulo-endothelial system. Table IV! depicts the observations relative to the neoplastic lesions cited within the bioassay report. In the report, 1/50 low dose and 5/49 high dose male mice were reported to carry undifferentiated carcinomas of the seminal vesicles. The authors cannot agree with the diagnoses presented in the NCI report. In the male control group secondary seminal vesicle neoplasms five high dose and one I plasms. The so-called undifferentiated carcinoma of the seminal vesicle within the low dose mouse was observed to be concomitant with a fibrosarcoma which was present grossly at necropsy and which involved the organs of the peritoneal cavity, .skeletal muscle of the abdominal wall and coccygeal vertebrae. The lesion represents a polypoid metastatic fibrosarcoma within a vestigial meso-nephric duct and, technically, does not even appear to be within the seminal vesicle ( Figure  21 ). In one of the high dose mice, a primary adenocarcinoma of the lung was concomitant with the so-called undifferentiated carcinoma of the seminal vesicle. The same type of cells were observed when the two neoplasms were compared histologically ( Figure 22 ). An hemangioendothelioma was observed envelop- ing the seminal vesicles in another high dose male mouse (Figures 23, 24 & 25) . This neoplasm was described at necropsy as engulfing the left seminal vesicle and exhibiting a dark red color. This tumor was classified in the NCI report as an undifferentiated carcinoma.
None of the so-called undifferentiated carcinomas of the seminal vesicles of the male mice were considered to be primary. The cell type and pattern of growth varied from tumor to tumor. A11 of the tumors were differentiated and appeared to occur as metastatic (secondary) n e o~l a s m s from 'primary differentiated lesions located elsewhere in the body. When the seminal vesicle tumors were examined independently by two sets of consultant pathologists, agreement could not be reached regarding the classification or site of origih of the tumors.Two pathologists were of the opinion that all of the tumors were metastic in origin, while three of the pathologists classified three of the five high dose and the single low dose tumors as anaplastic sarcomas. The remaining two high dose lesions, classified as tumors by NCI, were considered to be only inflammatory changes. Thus, whether the incidence of neoplasia was not statistically different between controls and high dose or whether the neoplasia was metastic in nature is really of academic interest only. The important point is that reserpine was not indicted as the cause of the seminal vesicle lesions by either group of consultant pathologists. However, despite these expert opinions, the NCI revised report remained unchanged! The authors continue to maintain that reserpine was not proven to be carcinogenic in male mice and they do not agree that the study in male mice "strongly indicates a possible increased risk to humans" as was stated in the NCI report. Table V depicts the 'findings relative to mammary tumors in female mice in the bioassay. The NCI report states, "Mammary tumors appear to be compound related since none of the lesions occurred in the control females? However, the authors' examination of the tissue sections from the control female mice revealed the presence of one fibroadenoma, one adenosquamous carcinoma which had been misdiagnosed in the NCI report, and a pre-neoplastic lesion and a metastatic tumor in the lung of a female mouse which was believed to have been misinterpreted by the bioassay investigators as a primary lung neoplasm and which may represent a metastatic mammary tumor.
MOUSE MAMMARY GLANDS
The mammary tumors designated as "mixed tumors, malignant", in the NCI report were originally diagnosed by the NCI pathol- --ogists as fibroadenomas. These latter diagnoses survived the scrutiny of the pathologists involved in a subsequent review of the tissue sections; however, under the direction of the Pathology Working Group of NCI they were changed by the original pathologists at a later date from ''fibroadenoma" to "mixed tumors, malignant", No explanation appears in the documentation at the repository where the study is stored. Furthermore, according to the NCI report, ''Malignant mixed tumors have also been classified as adenocarcinoma, Type C." Dunn's classification of mouse mammary tumors has been used extensively in the analyses of tumors with varied histologic types in a number of inbred strains of mice with or without the milk agent (17) . The system has great value when dealing with inbred strains wherein are found a predictable frequency of mammary tumor types. It is interesting to note that there is no predictable frequency of mammary tumors in the hybrid strain of mouse used in the bioassay program (31). According to Dunn's c~assification, the synonyms for adenocarcinoma Type C are fibroadenoma and adenofibroma. The tumor is composed of multiple dilated acini of varying size which are lined by a single layer of cuboidal epithelium and surrounded by spindle cells. The connective tissue stroma usually appears edematous. Type C is most frequently found in very old mice that lack the milk agent. In the absence of the predictability for inbred strains of mice, the classification system used in the NCI report seems inappropriate and misleading. Benign fibroadenomas cannot be classified as mixed tumors, malignant, or adenocarcinoma Type C according to Dunn's classification system. The authors fully concur with the diagnoses which were originally made on mammary tissues of treated mice by the reading pathologists: however, at some point after the initial interpretations were made, and after the completion of the quality assurance inspection, the diagnoses of "mixed tumors, malignant," were imposed. The NCI terminology ._ used to describe the mammary neoplasms in. i. this particular NCI report has no scientific-. validity and should never have been used.
Both groups of consultants considered the NCI classification inappropriate, but to no avail. Only by lumping benign fibroademas as "mixed tumors, malignant", could the NCI conclusion that "females had an increased incidence of mammary cancer" be justified.
~ONCLUSIONS AND ASSESSMENT
After an extensite, critical review of pathology material from the reserpine bioassay, it is the opinion of the authors that reserpine was not proven to be carcinogenic in male rats and in mice of both sexes as claimed in the report. This conclusion, which is alSo corroborated by a number of independent consulting pathologists, is based on the following information.: 1) An inadequate examination of the adrenal medullas from male rats (only 65% of the test males had representative sections of the medulla), which precluded a meaningful evaluation, 2) Inconsistent criteria in the diagnosis of adrenal medullary neoplasia and hyperplasia. 3) An absence of confirmatory histological techniques for distinguishing neoplastic from hyperplastic adrenal medullary lesions. 4) Inadequate examination and analysis of mouse seminal vesicle lesions. 5) Use of diagnoses of convenience which lumped mouse seminal vesicle lesions into a convenient but inaccurate counting category. 6 ) Use of diagnoses of convenience which lumped benign mouse mammary tumors into an unwarranted malignant category. 7) Blatant disregard for consultant expert opinions whenever they did not conform to those of the NCI, especially in regard to the controversial lesions in mice. The authors also contend that the conclusions in the bioassay report stating, "Our present study in rats and mice strongly indicates a potential risk to humans" is erroneous and unwarranted for the following reasons:
1) The evaluation of the carcinogenicity of chemicals cannot be based exclusively on chronic testing in animals because the mode of action is not revealed and this information is crucial for proper risk assessment in man (32).
-2) Potent, hormonally active drugs which affect the endocrine system often have the ability to shift tumor incidences in rodents, especially if given at high, unphysiological levels (32). Such shifts were apparent in the reserpine bioassay although they were not considered in the risk evaluation. The reported increased incidence of male rat adrenal medul-lary hyperplasia/neoplasia and female mouse mammary fibroadenomas were offset by concurrent, statistically significant decreases in male rat pituitary adenomas/carcinomas and lymphomas/leukemias; female rat endometrial polyps and C cell carcinomas of the thyroid; and male mice hepatocellular carcinomas and adenomas. 3 ) An increase in mammary cancer in mice, even if it were present, could not be extrapolated to man. This was clearly documented in the FDA Toxicology Advisory Comm~ttee Report on Antipsychotic Drugs dated August 12,1977. The committee, consisting of distinguished experts from academia and government, including the NCI, concluded that, "There are major differences in hormonal and reproductive p h y s~o l o~y between rodents and humans, including some related to the role of prolactin. At present, the Committee feels there is insufficient evidence to extrapolate from mice and rats to humans with respect tothe role of profactin in mammary carcinogenesis. It is therefore, the opinion of the Advisory Committee that the rodent studies are not relevant to a determination of the magn~tude of the potential €or human risk from mammary cancer." 4) Recent well designed human clinical case control. and cohort studies show little or no evidence of an increased risk of breast cancer in women. The most recent (February 1980) draft of the IARC Working Group on the Evaluation of the Carci~ogenic Risk of Chemicals to Humans concludes that, "The studies in humans are not consistent in showing an increase in risk of breast cancer associated with reserpine use, and considering all studies together and the methodological problems of same, such an increase appears unlikely. Because of sampling variation, however, a small increase ip risk (of the order of 50% or less) cannot be ruled out". Based on the material pesented, the authors feel that the results of the bioassay are distorted and the extr~polated risks to man exaggerated. Rules for weighing the evidence €or carcinogenicity from bioassays have not been established to date and in their absence, great care must be taken to consider all aspects in the carcino~enici~y evaluation. Finally, a simple and ex~editious appeal system for resolv-ing scientific disputes must be established. At the present time, reviey and resolution of scientific differences does not occur in an impartial manner and this deficiency should be corrected.
